What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neuropathic Pain
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the treatment of neuropathic pain.”In the company’s words, NCT04666714 on ClinicalTrials.gov
Other drugs for Neuropathic Pain
- Pregabalin XRBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- SP-102Semnur Pharmaceuticals, Inc. · Phase 3
- HalneuronDogwood Therapeutics Inc. · Phase 2
- VMD-3866VM Therapeutics LLC · Phase 2
- HL-1186Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2
- AFA-281Afasci Inc · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Sep 2025 | Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026